Drug Trial Radar · NCT03594435
Ibudilast for the Treatment of Alcohol Use Disorder
Last checked: Nov 19, 2026Latest source record: Nov 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
102
Actual
Start
Oct 1, 2018
Primary completion
Apr 19, 2023
Study completion Apr 19, 2023
Sponsor
- Lead sponsor
- University of California, Los AngelesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute on Alcohol Abuse and Alcoholism (NIAAA); MediciNova
- First posted
- Jul 20, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a double-blind, placebo-controlled randomized clinical trial of Ibudilast (IBUD) (50mg twice a day) for the treatment of Alcohol Use Disorder (AUD). Eligible participants will undergo a 12-week medication treatment period and 5 in-person visits over 16 weeks.
Conditions
- Alcohol Use Disorder
Interventions
IbudilastDrug
targets neurotrophin signaling and neuroimmune function
Placebo oral capsuleDrug
matched to active drug, ibudilast
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Heavy Drinking DaysTime frame: 12 week-treatment period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UCLA Addictions Laboratory
Los Angeles, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.